Pharmaceutical - Pharmaceutical, North America, Forest Laboratories

Forest Labs files law suit against several drugmakers for Namenda XR patent infringement


US drugmaker Forest Laboratories, together with Merz Pharma and Adamas Pharmaceuticals, has filed a law…

Adamas PharmaceuticalsForest LaboratoriesLegalMerz PharmaceuticalsNamendaNeurologicalNorth AmericaPatentsPharmaceuticalSun Pharmaceutical IndustriesTeva Pharmaceutical IndustriesUSAWockhardt

Forest debuts MMD drug Fetzima in US pharmacies


US drugmaker Forest Laboratories says that Fetzima (levomilnacipran ER capsules) is now available in…

FetzimaForest LaboratoriesMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalPierre FabreUSA

Forest spends $240 million for US rights to Saphris; streamlines operations


US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

FDA calls for more info from Forest and Gedeon Richter on cariprazine


The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application…

cariprazineForest LaboratoriesGedeon RichterNeurologicalNorth AmericaPharmaceuticalRegulation

Forest Labs reports rise in sales and EPS doubles in second quarter results


Forest Laboratories has released its second quarter results which showed that net sales for the quarter…

BystolicCNS DiseasesDalirespFinancialForest LaboratoriesLinzessNamendaNorth AmericaPharmaceuticalRespiratory and PulmonarySavellaTeflaroTudorza PressairViibryd

Forest Labs names new CEO to replace Howard Solomon


US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September…

BoardroomFinancialForest LaboratoriesNorth AmericaPharmaceutical

Forest Labs and Almirall opt to delay US filing for combo COPD drug


USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Forest Labs and Fabre's MMD drug gains FDA approval


US drugmaker Forest Laboratories (NYSE: FRX) and France-based independent Pierre Fabre Laboratories have…

FetzimaForest LaboratorieslevomilnacipranNeurologicalNorth AmericaPharmaceuticalPierre FabreRegulation

Forest agrees another license deal for Bystolic


US drugmaker Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings have reached a settlement…

Amerigen PharmaceuticalsBystolicCardio-vascularForest LaboratoriesGenericsLicensingNorth AmericaPharmaceutical

Insights on the US Alzheimer's disease market


The treatment of Alzheimer's disease (AD) offers a compelling commercial opportunity for the pharmaceutical…

AriceptEisaiExelonForest LaboratoriesGenericsMarkets & MarketingNamendaNeurologicalNorth AmericaNovartisPfizerPharmaceutical

FDA nod for use of Ironwood and Forest's Linzess in certain cases of IBS and constipation


The US Food and Drug Administration last week approved Linzess (linaclotide), co-marketed by US drugmakers…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideLinzessNorth AmericaPharmaceuticalRegulation

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD


US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA extends review of Ironwood and Forest's linaclotide to September


The US Food and Drug Administration has told USA-based drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD)…

Forest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulation

Forest Labs buys Bystolic rights from Janssen for $357 million


Forest Laboratories, (NYSE: FRX) says it has acquired all US patents and other US and Canadian intellectual…

BystolicCardio-vascularForest LaboratoriesJanssen PharmaceuticaJohnson & JohnsonLicensingNorth AmericaPharmaceuticalSavella

US FDA delays approval of Almirall and Forest Laboratories' COPD drug


The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH


The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12…

aclidiniumAlmirallBiotechnologyChelsea TherapeuticsEkliraForest LaboratoriesNeurologicalNorth AmericaNortheraPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall


US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Back to top